Checkpoint inhibitor combination shows promise in Merkel cell carcinoma
Dual checkpoint inhibitor blockade could be a promising first-line and salvage therapeutic option for advanced Merkel cell carcinoma, say researchers.
List view / Grid view
Dual checkpoint inhibitor blockade could be a promising first-line and salvage therapeutic option for advanced Merkel cell carcinoma, say researchers.
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
Moffitt researchers conducted a Phase III trial which found durvalumab to increase the survival of patients with non-small cell lung cancer...
Scientists have tried combining drugs in an effort to prevent resistance development that eventually leads to cancer regrowth in melanoma patients.
Researchers at the Moffitt Cancer Center in Florida have combined single-cell imaging of cancer cells in mice with mathematical modelling to establish which drug characteristics determine its efficacy.
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
New study shows ALK inhibitor ceritinib may have the ability to be used for more than ALK-rearranged non-small cell lung cancer...
Scientists have developed an improved vaccine commonly associated with cervical cancer...